PI3K/Akt/CREB activator 1

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2708177-73-3

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

PI3K/Akt/CREB activator 1 (compound AE-18) 是一种口服有效的PI3K/Akt/CREB的激活剂。PI3K/Akt/CREB activator 1 通过 PI3K/Akt/CREB 通路上调脑源性神经营养因子，促进神经元增殖，诱导 Neuro-2a 细胞分化成神经元样形态，加速海马原代神经元轴突-树突极化的建立。PI3K/Akt/CREB activator 1 可用于血管性痴呆 (VaD) 的研究。

生物活性

PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally activePI3K/Akt/CREBactivator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD)^[1].

体外研究
(In Vitro)

PI3K/Akt/CREB activator 1 (compound AE-18; 10 and 20 μM; 48 h) induces neurite outgrowth and proliferation through upregulating BDNF via the PI3K/Akt/CREB pathway Neuro-2a cells^[1].
PI3K/Akt/CREB activator 1 (10 and 20 μM; neurons) enhances neuronal differentiation and axon-dendrite polarization in cultured hippocampal neurons through the PI3K/AKT signal pathway^[1].

Western Blot Analysis^[1]

Cell Line:	Neuro-2a cells
Concentration:	10 and 20 μM
Incubation Time:	48 hours
Result:	Increased the expressions of BDNF and the phosphorylated form of AKT (pAKT) and CREB (pCREB).

体内研究
(In Vivo)

PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO)^[1].
PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO^[1].

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model^[1]
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 6 weeks
Result:	Promoted the recovery of CBF after BCCAO.

Animal Model:	Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model^[1]
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; daily, for 5 days
Result:	Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group. Improved cognitive deficits in CCH rat model.

分子量

381.32

Formula

C₁₉H₁₅F₄NO₃

CAS 号

2708177-73-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.